Literature DB >> 6586195

Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain.

P W Glimcher, A A Giovino, D H Margolin, B G Hoebel.   

Abstract

Opiates are known to be reinforcing when injected into the ventral tegmental area (VTA). The present study produced conditioned reinforcement with local injections of exogenous d-ala2-met5-enkephalinamide (DALA), a potent analogue of met-enkephalin, and with thiorphan , an enkephalinase inhibitor which protects endogenous opiates from enzymic degradation. In a conditioned place preference paradigm, rats received injections of DALA (1.0, 3.0, or 8.0 micrograms), thiorphan (60 micrograms), and/or naloxone (10 micrograms), or saline vehicle. Conditioned reinforcement was obtained with 8.0 micrograms of DALA and also with thiorphan but not with thiorphan plus naloxone. This suggests that reward can be generated by endogenous opiates in the VTA. Tests during the light phase and dark phase suggested that diurnal periodicity may play a role in opiate reward. It is concluded that the VTA can generate conditioned reward through transmitter-receptor interaction involving an endogenous opiate substrate which is probably enkephalinergic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6586195     DOI: 10.1037//0735-7044.98.2.262

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  10 in total

1.  Opioid delta agonists and endogenous enkephalins induce different emotional reactivity than mu agonists after injection in the rat ventral tegmental area.

Authors:  G Calenco-Choukroun; V Daugé; G Gacel; J Féger; B P Roques
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 3.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

4.  Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of mu and delta opioid receptors in rat brain.

Authors:  G Waksman; E Hamel; M C Fournié-Zaluski; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

Review 5.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

6.  Naloxone blockade of amphetamine place preference conditioning.

Authors:  K A Trujillo; J D Belluzzi; L Stein
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 7.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

Review 8.  Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake.

Authors:  Nicole M Avena; Pedro Rada; Bartley G Hoebel
Journal:  Neurosci Biobehav Rev       Date:  2007-05-18       Impact factor: 8.989

Review 9.  Sugar Addiction: From Evolution to Revolution.

Authors:  David A Wiss; Nicole Avena; Pedro Rada
Journal:  Front Psychiatry       Date:  2018-11-07       Impact factor: 4.157

Review 10.  The role of enkephalinergic systems in substance use disorders.

Authors:  Lauren G Rysztak; Emily M Jutkiewicz
Journal:  Front Syst Neurosci       Date:  2022-08-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.